Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

159P - The impact of the extent of the type of primary breast cancer (BC) surgery from the analysis of historical Italian trials

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Elia Biganzoli

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101221-101221. 10.1016/esmoop/esmoop101221

Authors

E. Biganzoli1, F. Bianchi2, P. Boracchi3, G. Biganzoli3, G. Marano3, E. Tagliabue4, C. Desmedt5, R. Demicheli3

Author affiliations

  • 1 Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Milan/IT
  • 2 UNIMI - Università degli Studi di Milano Statale, Milan/IT
  • 3 Unit of Medical Statistics, Biometry and Epidemiology, Milano/IT
  • 4 Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan/IT
  • 5 KU Leuven - VIB Campus Gasthuisberg, 3000 - Leuven/BE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 159P

Background

Breast-conserving surgery (BCS) is the treatment of choice for women with early-stage BC. Several studies indicated a better outcome in patients undergoing BCS plus radiotherapy (RT) in comparison with mastectomy (MAST) +/- RT (PMID:33950173, 27344114). Indeed, in comparison with MAST, BCS reduces the extent of surgery, but the addition of radiotherapy (RT) makes it hard to understand whether the differences in outcome may be attributed to the extent of the surgery only.

Methods

We performed a competing risks re-analysis in terms of dynamics and crude cumulative incidence (CCI), of distant recurrence free survival (DRFS) from two historical randomized clinical trials which of the Istituto Nazionale dei Tumori of Milan: the “Milan 1” trial (n = 701; 1973-1980, PMID:7015141) which compared MAST with BCS plus RT (BCS+RT) and the “Milan 3” trial (n = 567; 1987-1989, PMID: 8387637) which adopted the same surgical conservative approach with (BCS +RT) or without (BCS -RT) RT. Clinical features such as primary tumour size, axillary lymph node status (N) and menopausal status were considered.

Results

Concerning distant recurrence (DR) dynamics in Milan 1 trial, evidence of a different intensity of cause-specific hazard was found among subgroups related to surgery and lymph-node status (test of interaction effect: P=0.005), though with similar multi-peaked hazard patterns. Indeed, we observed that a MAST-related worse outcome is present in women with positive N (N+). Analysis of CCI reveals that, for the subgroup of N+ patients in Milan 3 trial, removal of RT from BCS (BCS -RT) results in 30% higher incidence of DR, comparable to the difference between MAST N+ and BCS+RT N+ patients in the Milan 1 trial.

Conclusions

In this re-analysis of historical randomized clinical trials, we report that the worse outcome of MAST in comparison with BCS may be mainly attributed to higher extensive surgery and that the effect of the extent of the surgery without RT is mostly confined to patients with N+ BC. The effect of RT, as assessed by the re-analysis of Milan 3 trial, is likely related to a combined effect of the control of local recurrences, and the potential systemic effect of RT.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.